FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617055690> ?p ?o ?g. }

• W2617055690 endingPage "544" @default.
• W2617055690 startingPage "532" @default.
• W2617055690 abstract "Objectives: To evaluate the efficacy, compliance, safety and economic cost for Fosfomycin trometamol and Nitofurantoin in uncomplicated lower urinary tract infections during pregnancy. Background: Nitofurantoin and Fosfomycin trometamol are recommended as the first-line agents for treatment of urinary tract infections (UTIs) in the latest guidelines endorsed by the Infectious Diseases Society of America (IDSA) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). Fosfomycin is bactericidal and inhibits bacterial cell wall biogenesis and reduces bacterial adherence to uroepithelial cells. Fosfomycin has broad antibacterial activity against both Gram-positive and Gram-negative pathogens, as Escherichia coli, Escherichia faecalis, and various Gram-negatives like Citrobacter and Proteus. Both Nitofurantoin and Fosfomycin are category B in pregnancy. Patients and Methods: This study was conducted at Tanta University Hospitals in the period from June, 1, 2015 to January, 1, 2017. Patients were recruited from outpatient clinics of Obstetrics and Gynecology and Urology Departments presenting with asymptomatic bacteruria or cystitis. Patients were allocated randomly into 2 groups: group I (n = 50 cases) received Fosfomycin therapy and group II (n = 50 cases) received Nitofurantoin therapy (n = 50 cases). After treatment, evaluation of patient symptoms, organism count, patient compliance and cost of treatment were done. Results: The enrolled patients were suffering from lower urinary tract infections; asymptomatic bacteruria (17 cases) or cystitis (83 cases). Ten patients were excluded. The demographic data of included patients were not significant for both groups. Complete relief (100%) of symptoms 5 days after start of treatment was noticed in Fosfomycin group while improvement of symptoms after 5 day-treatment was noticed in 86.49% in Nitofurantoin group (p-value = 0.030). The side effects were recorded in 7 cases (18.42%) in Fosfomycin group compared to (35.14%) with significant difference in the reported side effects, (p-value = 0.003). Compliance was 38/38 (100%) in Fosfomycin group compared to 34/37 (91.89%) in Nitrofuantoin group (p-value = 0.001). Resistance was very minimal in Fosfomycin group where 1/38 case (2.63%) reported resistance for treatment compared to 8/37 cases (21.62%) in Nitofurantoin group (p-value = 0.001). Conclusion: Fosfomycin trometamine proved to be safe, effective, and has limited resistance. Moreover higher patient compliance and fewer side effects were recommending Fosfomycin to be a first choice drug for uncomplicated lower urinary tract infections during pregnancy at Tanta University." @default.
• W2617055690 created "2017-06-05" @default.
• W2617055690 creator A5047799741 @default.
• W2617055690 creator A5082101296 @default.
• W2617055690 creator A5086794385 @default.
• W2617055690 creator A5090068455 @default.
• W2617055690 date "2017-01-01" @default.
• W2617055690 modified "2023-10-14" @default.
• W2617055690 title "Fosfomycin Therapy for Non-Complicated Lower Urinary Tract Infections during Pregnancy: Tanta University Experience" @default.
• W2617055690 cites W1551398445 @default.
• W2617055690 cites W1736511690 @default.
• W2617055690 cites W1885407530 @default.
• W2617055690 cites W192974887 @default.
• W2617055690 cites W1968991031 @default.
• W2617055690 cites W1969867618 @default.
• W2617055690 cites W1973613325 @default.
• W2617055690 cites W1976246246 @default.
• W2617055690 cites W1985894646 @default.
• W2617055690 cites W2000754271 @default.
• W2617055690 cites W2013230343 @default.
• W2617055690 cites W2015737341 @default.
• W2617055690 cites W2020421691 @default.
• W2617055690 cites W2026052641 @default.
• W2617055690 cites W2050227017 @default.
• W2617055690 cites W2056774979 @default.
• W2617055690 cites W2058162439 @default.
• W2617055690 cites W2073566944 @default.
• W2617055690 cites W2086228598 @default.
• W2617055690 cites W2091824699 @default.
• W2617055690 cites W2096023246 @default.
• W2617055690 cites W2101182625 @default.
• W2617055690 cites W2120750073 @default.
• W2617055690 cites W2128480475 @default.
• W2617055690 cites W2132383241 @default.
• W2617055690 cites W2139784920 @default.
• W2617055690 cites W2151057735 @default.
• W2617055690 cites W2156566731 @default.
• W2617055690 cites W2167495142 @default.
• W2617055690 cites W2168476362 @default.
• W2617055690 cites W2169123045 @default.
• W2617055690 cites W2176594164 @default.
• W2617055690 cites W2186600912 @default.
• W2617055690 cites W2279031885 @default.
• W2617055690 cites W2345881324 @default.
• W2617055690 cites W2387065511 @default.
• W2617055690 cites W2394999101 @default.
• W2617055690 cites W2410383325 @default.
• W2617055690 cites W2528299860 @default.
• W2617055690 cites W2591580087 @default.
• W2617055690 cites W27804729 @default.
• W2617055690 cites W2129423383 @default.
• W2617055690 doi "https://doi.org/10.4236/ojog.2017.75056" @default.
• W2617055690 hasPublicationYear "2017" @default.
• W2617055690 type Work @default.
• W2617055690 sameAs 2617055690 @default.
• W2617055690 citedByCount "1" @default.
• W2617055690 countsByYear W26170556902021 @default.
• W2617055690 crossrefType "journal-article" @default.
• W2617055690 hasAuthorship W2617055690A5047799741 @default.
• W2617055690 hasAuthorship W2617055690A5082101296 @default.
• W2617055690 hasAuthorship W2617055690A5086794385 @default.
• W2617055690 hasAuthorship W2617055690A5090068455 @default.
• W2617055690 hasBestOaLocation W26170556901 @default.
• W2617055690 hasConcept C126322002 @default.
• W2617055690 hasConcept C2777910003 @default.
• W2617055690 hasConcept C2778897966 @default.
• W2617055690 hasConcept C29456083 @default.
• W2617055690 hasConcept C501593827 @default.
• W2617055690 hasConcept C71924100 @default.
• W2617055690 hasConcept C77411442 @default.
• W2617055690 hasConcept C86803240 @default.
• W2617055690 hasConcept C89423630 @default.
• W2617055690 hasConceptScore W2617055690C126322002 @default.
• W2617055690 hasConceptScore W2617055690C2777910003 @default.
• W2617055690 hasConceptScore W2617055690C2778897966 @default.
• W2617055690 hasConceptScore W2617055690C29456083 @default.
• W2617055690 hasConceptScore W2617055690C501593827 @default.
• W2617055690 hasConceptScore W2617055690C71924100 @default.
• W2617055690 hasConceptScore W2617055690C77411442 @default.
• W2617055690 hasConceptScore W2617055690C86803240 @default.
• W2617055690 hasConceptScore W2617055690C89423630 @default.
• W2617055690 hasIssue "05" @default.
• W2617055690 hasLocation W26170556901 @default.
• W2617055690 hasOpenAccess W2617055690 @default.
• W2617055690 hasPrimaryLocation W26170556901 @default.
• W2617055690 hasRelatedWork W1987215768 @default.
• W2617055690 hasRelatedWork W1995188757 @default.
• W2617055690 hasRelatedWork W2016679923 @default.
• W2617055690 hasRelatedWork W2057721052 @default.
• W2617055690 hasRelatedWork W2116001782 @default.
• W2617055690 hasRelatedWork W2314711404 @default.
• W2617055690 hasRelatedWork W2423950151 @default.
• W2617055690 hasRelatedWork W2763646354 @default.
• W2617055690 hasRelatedWork W4229900919 @default.
• W2617055690 hasRelatedWork W4350505 @default.
• W2617055690 hasVolume "07" @default.
• W2617055690 isParatext "false" @default.
• W2617055690 isRetracted "false" @default.

• next